Drug Profile
Research programme: skin disorder therapeutics - LEO Pharma
Alternative Names: LEO 90110; LP 0067; LP0017Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator LEO Pharma
- Class Small molecules
- Mechanism of Action CXCR4 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atopic dermatitis; Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atopic-dermatitis in Denmark
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psoriasis in Denmark
- 18 Apr 2012 LEO Pharma plans a phase I trial for Psoriasis in France (NCT01580488)